Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

  • Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders
  • Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid
  • The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid
  • Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund
  • The company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC)
  • Amniotics has also an, by Läkemedelsverket, approved GMP facility to produce Advanced Therapy Medicinal Products (ATMPs)
Laura M
Laura M
Laura is a financial reporter, editor, and researcher with a particular interest in fintech innovation, capital markets, and the evolving global banking landscape.

You May Also Like

Venmo Strengthens Global Transfers by Allowing Payments to PayPal Accounts

Venmo users can now send money internationally to PayPal accounts.Highlights: Venmo now allows users to send money to...

Talos and Nasdaq Strengthen On-Chain and Off-Chain Collateral Workflow

New partnership enhances digital asset handling and collateral management.Highlights: Talos and Nasdaq collaborate to streamline collateral workflows.Partnership aims...

FCA Restricts Use of Sensitive Data in AI Trial with Palantir

Regulatory concerns arise over data handling protocols in AI trials.Highlights: FCA criticized for using sensitive data in AI...

Bank of Ireland Strengthens AI Readiness for Staff Training

New initiatives prepare employees for an AI-driven banking landscape.Highlights: Bank of Ireland launches AI training initiatives for staff.Employees...